Metabolic syndrome and psoriatic arthritis were highly prevalent comorbidities in patients with plaque psoriasis.
The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.
Researchers observed a significant reduction in the incidence of acute anterior uveitis among patients with ankylosing spondylitis treated with golimumab.
Antidrug antibody incidence was higher using drug-tolerant vs original enzyme immunoassays in patients treated with golimumab.
The guideline is jointly authored by the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).
Data regarding assessment of systemic inflammation using acute-phase reactants are limited.
C-reactive protein levels may be an effective predictive measure to assess treatment response in patients with ankylosing spondylitis.
The TORTUGA trial investigated the efficacy and safety of filgotinib for the treatment of patients with active ankylosing spondylitis.
Researchers compared definitions of remission and low disease activity in patients with psoriatic arthritis.
The incidence of vertebral fracture in SpA was lower than that reported in previous studies.
Investigators examined the performance of various definitions in patients with PsA and psoriasis.
CVD risk factors were associated with red blood cell distribution and albumin and red blood cell distribution was also associated with age, albumin, hemoglobin, race, HLAB27 status, CRP, and statin treatment.
Researchers reviewed the accuracy and characteristics of questionnaire-based PsA screening tools.
Data identified both clinical and employment factors that may predict poor work outcomes in patients with axial spondyloarthritis.
Higher radiographic progression was associated with increased inflammation and damage in early axial spondyloarthritis.
Results do not suggest that separate diagnostic strategies for men and women are required.
Data show that filgotinib is effective for the treatment of active psoriatic arthritis.
TNFi therapy failed to prevent the development of joint ankylosis despite a substantial reduction in inflammation with TNFi therapy.
To compare the characteristics of patients who discontinued TNFis with those who did not, researchers used the Corrona PsA/SpA Registry to identify patients with AS who were on a TNFi and had ≥2 follow-up visits.
Clinical improvements during treatment with TNF-α inhibitors was comparable between men and women with ankylosing spondylitis.
For patients with active radiographic axSpA and prior inadequate response or intolerance to 1 or 2 TNFi, ixekizumab treatment results in significant improvements vs placebo.
Christopher T. Ritchlin, MD, MPH, discusses updated bimekizumab data from the BE-ACTIVE trial.
Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.
The use of ustekinumab and secukinumab is associated with similar drug survival and efficacy among patients with psoriatic arthritis.
The genetic risk score may have lower costs than current testing methods.
The approval was based on data from a randomized, double-masked, placebo-controlled study of 90 pediatric patients aged 2 to < 18 years with active JIA-associated non-infectious uveitis.
Patients with psoriatic arthritis had greater entheseal insertion damage scores compared with patients with ankylosing spondylitis.
Results suggest that C-reactive protein testing should be repeated after at least 4 weeks.
Risk for type 2 diabetes, ischemic heart disease, and peripheral vascular disease was elevated among patients with psoriatic arthritis compared with the general population.
Findings suggest that repeating MRI of the sacroiliac joints after 3 months or 1 year in patients with chronic back pain and suspected axial spondyloarthritis was not useful.
Rheumatology Advisor Articles
- Ultrasonography in Gout: Potential Applications for Diagnosis and Patient Monitoring
- Immunogenicity of Golimumab Validated Using Novel Anti-Drug Antibody Detection Assay
- Similar Long-Term Outcomes in Early- vs Late-Onset Lupus Nephritis
- Radiographic Knee OA Not Correlated With Diabetes, Altered Glucose Metabolism
- Serum sRAGE Correlated With Disease Activity in Rheumatoid Arthritis
- Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments?
- Examining Insurance Complications in the Shared Decision Making Process for Rheumatoid Arthritis
- Smoking Linked to Cognitive Dysfunction in Fibromyalgia
- Patient Education Can Improve Chronic Disease Management
- Health-Enhancing Physical Activity Program Reduces Global Pain in RA
- Chronic Opioid Use Has Doubled Since 2002 Among Patients With RA
- Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus
- Flaws, Potential Solutions for Physician Incentive Programs Examined
- Metabolic Syndrome, Psoriatic Arthritis Highly Prevalent in Patients With Plaque Psoriasis
- Gene Polymorphisms Predict Response to Tocilizumab, Rituximab in RA